- Stocks
- Healthcare
- NASDAQ: CORT

Price (delayed)

$20.29

Market cap

$2.37B

P/E Ratio

23.59

Dividend/share

N/A

EPS

$0.86

Enterprise value

$2.32B

Corcept Therapeutics's debt has decreased by 34% YoY and by 19% QoQ

The P/E is 38% less than the 5-year quarterly average of 38.3 but 3% more than the last 4 quarters average of 22.9

The company's equity rose by 25% YoY but it fell by 2.4% QoQ

The EPS has declined by 7% since the previous quarter and by 7% year-on-year

CORT's net income is down by 6% QoQ and by 6% YoY

What are the main financial stats of CORT

Market
Valuations
Earnings

Shares outstanding

116.63M

Market cap

$2.37B

Enterprise value

$2.32B

Price to earnings (P/E)

23.59

Price to book (P/B)

4.66

Price to sales (P/S)

6.97

EV/EBIT

21.03

EV/EBITDA

20.59

EV/Sales

6.81

Revenue

$340.06M

EBIT

$110.13M

EBITDA

$112.51M

Free cash flow

$142.8M

Per share
Balance sheet
Liquidity

EPS

$0.86

Free cash flow per share

$1.22

Book value per share

$4.35

Revenue per share

$2.91

TBVPS

$4.73

Total assets

$552.4M

Total liabilities

$41.6M

Debt

$2.07M

Equity

$510.8M

Working capital

$369.02M

Debt to equity

0

Current ratio

10.09

Quick ratio

9.73

Net debt/EBITDA

-0.45

Margins
Efficiency
Dividend

EBITDA margin

33.1%

Gross margin

98.5%

Net margin

29.2%

Operating margin

32.4%

Return on assets

18.4%

Return on equity

20.1%

Return on invested capital

24.8%

Return on capital employed

21.5%

Return on sales

32.4%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Corcept Therapeutics stock price performed over time

Intraday

-0.15%

1 week

0.45%

1 month

-8.85%

1 year

24.86%

YTD

-22.44%

QTD

-7.77%

How have Corcept Therapeutics's revenue and profit performed over time

Revenue

$340.06M

Gross profit

$335.09M

Operating income

$110.13M

Net income

$99.41M

Gross margin

98.5%

Net margin

29.2%

The operating margin has contracted by 17% YoY and by 10% from the previous quarter

Corcept Therapeutics's operating income has decreased by 16% YoY and by 14% from the previous quarter

Corcept Therapeutics's net margin has decreased by 8% YoY and by 2.7% QoQ

CORT's net income is down by 6% QoQ and by 6% YoY

What is Corcept Therapeutics's growth rate over time

What is Corcept Therapeutics stock price valuation

P/E

23.59

P/B

4.66

P/S

6.97

EV/EBIT

21.03

EV/EBITDA

20.59

EV/Sales

6.81

The P/E is 38% less than the 5-year quarterly average of 38.3 but 3% more than the last 4 quarters average of 22.9

The EPS has declined by 7% since the previous quarter and by 7% year-on-year

The stock's price to book (P/B) is 54% less than its 5-year quarterly average of 10.1 and 4.9% less than its last 4 quarters average of 4.9

The company's equity rose by 25% YoY but it fell by 2.4% QoQ

CORT's P/S is 16% below its 5-year quarterly average of 8.3

The revenue has declined by 3.9% since the previous quarter

How efficient is Corcept Therapeutics business performance

CORT's ROIC is down by 43% year-on-year and by 21% since the previous quarter

CORT's return on assets is down by 33% year-on-year and by 11% since the previous quarter

The return on equity has declined by 33% year-on-year and by 11% since the previous quarter

The return on sales has declined by 17% year-on-year and by 10% since the previous quarter

What is CORT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for CORT.

How did Corcept Therapeutics financials performed over time

The company's total assets rose by 24% YoY but it fell by 3.4% QoQ

The total liabilities has grown by 16% YoY but it has contracted by 14% from the previous quarter

Corcept Therapeutics's debt is 100% lower than its equity

CORT's debt to equity has shrunk by 100% YoY

Corcept Therapeutics's debt has decreased by 34% YoY and by 19% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.